ARVN - NASDAQ
Arvinas, Inc.
$7.70
-3.8%Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
At a Glance
Live SnapshotArvinas, Inc. Management Team
Dr. John G. Houston Ph.D.
Chairperson, Chief Executive Officer & President
Compensation
$1,124,624
Dr. Randy Teel Ph.D.
Chief Business Officer
Compensation
$711,098
Mr. Andrew R. Saik
Chief Financial Officer & Treasurer
Compensation
$657,193
Dr. Noah Berkowitz M.D., Ph.D.
Chief Medical Officer
Compensation
$747,020
Ms. Angela M. Cacace Ph.D.
Chief Scientific Officer
Compensation
$696,153
Mr. Jared M. Freedberg J.D.
General Counsel & Corporate Secretary
Dr. Ian Taylor Ph.D.
President of Research & Development and Chairman of Scientific Advisory Board
Compensation
$553,937
Mr. Steve Weiss
Senior Vice President & Chief Human Resources Officer
Ms. Lisa Sinclair
Senior Vice President of Corporate Operations
Mr. David K. Loomis M.B.A.
Vice President & Chief Accounting Officer
Arvinas, Inc. Insider Positioning
During the last 12 months, insiders have purchased $495K and sold $862K worth of ARVN shares, resulting in $366K of net selling activity.
3 Months
20.0K
268.07K
52.1K
523.47K
-255K
-$255K
3-6 Months
0
0.00
27.7K
335.83K
-336K
-$336K
6-9 Months
30.0K
227.01K
230
2.27K
+225K
+$225K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Morrison Briggs
Director
$495K
Top Sellers
Berkowitz Noah
Officer: Chief Medical Officer
$249K
Saik Andrew
Officer: Chief Financial Officer
$172K
Teel Randy
Director, Officer: President And Ceo
$168K
Cacace Angela M
Officer: Chief Scientific Officer
$163K
Houston John G
Director
$62K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $366K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Negative recent trend with net selling. Insiders have reduced positions in recent months, which could signal caution.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
ARVN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 24, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 25, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 16, 2024 | May 29, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 16, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 26, 2021 | June 08, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 21, 2020 | June 03, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 12, 2019 | May 23, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.